{"id":860746,"date":"2025-06-16T08:11:05","date_gmt":"2025-06-16T12:11:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\/"},"modified":"2025-06-16T08:11:05","modified_gmt":"2025-06-16T12:11:05","slug":"immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\/","title":{"rendered":"Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CAMBRIDGE, Mass., June  16, 2025  (GLOBE NEWSWIRE) &#8212; Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced that it will host a conference call and live webcast at 8:00 am ET on June 17, 2025. The company is excited to provide updates from its ongoing Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients.<\/p>\n<p align=\"justify\">The conference call will be webcast live and archived in the Investor Relations section of Immuneering\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NXgTXm5505R7HnhnjE-HcyVBPf2ngSNrfIOagchfgXWLsbazCCZgmv8AdS2mzRJOJibaQ0F8qL_cqXpbcN1TY5odURWNSCTaVlXfJWYMrosk-kEIDU7r25dzLJwWpNNpSsMTAEBM3j4q-WCzAhGJm_9NoH2bgnXFy2WQOH4Bom_3BjzGE1X_YPtOTfuRFx_7\" rel=\"nofollow\" target=\"_blank\">Events &amp; Presentations | Immuneering Corporation<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Immuneering Corporation<\/strong>\n      <\/p>\n<p align=\"justify\">Immuneering is a clinical-stage oncology company outpacing cancer to help patients outlive their disease. The Company\u2019s lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. IMM-1-104 is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company\u2019s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com.<\/p>\n<p>\n        <strong>Media Contact:<\/strong>\u00a0<br \/>Jenna Urban\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=35yUiM6aRVo5ZjQJm-iHS6GVLeolOxrFz-dWlzWG7lLKfRl5OD6CtaFOQ6e6PXrsG_OK7zMNdahua3_vuQTe5LBZZfF-_aq6FWyKMSKEFac=\" rel=\"nofollow\" target=\"_blank\">jurban@cglife.com<\/a><\/p>\n<p>\n        <strong>Investor Contact:<\/strong>\u00a0<br \/>Laurence Watts\u00a0<br \/>619-916-7620\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WUhctj8R68DYoDIFhEcTYUcdJc8MjCmVNjYfuuq-jwgzm-85E84GyoCbEeXezXersanhGkU-BnJapritGnJ-zYnZxT7B3QMmXxGFiPa0g2GobO-i7h0Tp4OwhaqrSxEa\" rel=\"nofollow\" target=\"_blank\">laurence@newstreetir.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2OTA1OSM2OTkyNDA1IzIyMDkzOTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Y2M4ZDk1ZDYtNzMwMS00MDViLTg1ZTMtNDYyZjFmMzkwMjI4LTEyMjA5NDktMjAyNS0wNi0xNi1lbg==\/tiny\/Immuneering-Corporation.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) &#8212; Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced that it will host a conference call and live webcast at 8:00 am ET on June 17, 2025. The company is excited to provide updates from its ongoing Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients. The conference call will be webcast live and archived in the Investor Relations section of Immuneering\u2019s website at Events &amp; Presentations | Immuneering Corporation. About Immuneering Corporation Immuneering is a clinical-stage oncology company outpacing cancer to help patients outlive their disease. The Company\u2019s lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-860746","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) &#8212; Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced that it will host a conference call and live webcast at 8:00 am ET on June 17, 2025. The company is excited to provide updates from its ongoing Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients. The conference call will be webcast live and archived in the Investor Relations section of Immuneering\u2019s website at Events &amp; Presentations | Immuneering Corporation. About Immuneering Corporation Immuneering is a clinical-stage oncology company outpacing cancer to help patients outlive their disease. The Company\u2019s lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of &hellip; Continue reading &quot;Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-16T12:11:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2OTA1OSM2OTkyNDA1IzIyMDkzOTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025\",\"datePublished\":\"2025-06-16T12:11:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\\\/\"},\"wordCount\":209,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2OTA1OSM2OTkyNDA1IzIyMDkzOTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\\\/\",\"name\":\"Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2OTA1OSM2OTkyNDA1IzIyMDkzOTY=\",\"datePublished\":\"2025-06-16T12:11:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2OTA1OSM2OTkyNDA1IzIyMDkzOTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2OTA1OSM2OTkyNDA1IzIyMDkzOTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\/","og_locale":"en_US","og_type":"article","og_title":"Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - Market Newsdesk","og_description":"CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) &#8212; Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced that it will host a conference call and live webcast at 8:00 am ET on June 17, 2025. The company is excited to provide updates from its ongoing Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients. The conference call will be webcast live and archived in the Investor Relations section of Immuneering\u2019s website at Events &amp; Presentations | Immuneering Corporation. About Immuneering Corporation Immuneering is a clinical-stage oncology company outpacing cancer to help patients outlive their disease. The Company\u2019s lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of &hellip; Continue reading \"Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-16T12:11:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2OTA1OSM2OTkyNDA1IzIyMDkzOTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025","datePublished":"2025-06-16T12:11:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\/"},"wordCount":209,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2OTA1OSM2OTkyNDA1IzIyMDkzOTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\/","name":"Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2OTA1OSM2OTkyNDA1IzIyMDkzOTY=","datePublished":"2025-06-16T12:11:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2OTA1OSM2OTkyNDA1IzIyMDkzOTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2OTA1OSM2OTkyNDA1IzIyMDkzOTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-provide-updates-from-phase-2a-clinical-trial-of-imm-1-104-in-first-line-pancreatic-cancer-patients-on-tuesday-june-17-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/860746","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=860746"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/860746\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=860746"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=860746"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=860746"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}